Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Molecular pathways and targets in prostate cancer.

Shtivelman E, Beer TM, Evans CP.

Oncotarget. 2014 Sep 15;5(17):7217-59. Review.

2.

Pathways and therapeutic targets in melanoma.

Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE.

Oncotarget. 2014 Apr 15;5(7):1701-52. Review.

3.

Molecular pathways and therapeutic targets in lung cancer.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R.

Oncotarget. 2014 Mar 30;5(6):1392-433. Review.

4.

Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS.

Chen V, Staub RE, Fong S, Tagliaferri M, Cohen I, Shtivelman E.

PLoS One. 2012;7(2):e30300. doi: 10.1371/journal.pone.0030300. Epub 2012 Feb 3.

5.

Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle.

Chen V, Staub RE, Baggett S, Chimmani R, Tagliaferri M, Cohen I, Shtivelman E.

PLoS One. 2012;7(1):e30107. doi: 10.1371/journal.pone.0030107. Epub 2012 Jan 17.

6.

Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study.

Klawitter J, Klawitter J, Gurshtein J, Corby K, Fong S, Tagliaferri M, Quattrochi L, Cohen I, Shtivelman E, Christians U.

Int J Cancer. 2011 Dec 15;129(12):2945-57. doi: 10.1002/ijc.25965. Epub 2011 Apr 20.

7.

CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation.

Chen V, Shtivelman E.

Cell Cycle. 2010 Dec 15;9(24):4941-53. Epub 2010 Dec 15.

8.

Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2.

Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman DC.

Breast Cancer Res Treat. 2011 Oct;129(3):777-84. doi: 10.1007/s10549-010-1273-5. Epub 2010 Dec 1.

PMID:
21120602
9.

Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression.

DeLisser H, Liu Y, Desprez PY, Thor A, Briasouli P, Handumrongkul C, Wilfong J, Yount G, Nosrati M, Fong S, Shtivelman E, Fehrenbach M, Cao G, Moore DH, Nayak S, Liggitt D, Kashani-Sabet M, Debs R.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18616-21. doi: 10.1073/pnas.1004654107. Epub 2010 Oct 6. Erratum in: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3821. Nyack, Shruti [corrected to Nayak, Shruti].

10.

CC3/TIP30 affects DNA damage repair.

Fong S, King F, Shtivelman E.

BMC Cell Biol. 2010 Apr 7;11:23. doi: 10.1186/1471-2121-11-23.

11.

A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.

Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL.

Breast Cancer Res Treat. 2010 Feb;120(1):111-8. doi: 10.1007/s10549-009-0678-5.

PMID:
20054647
12.

Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid.

Chu R, Zhao X, Griffin C, Staub RE, Shoemaker M, Climent J, Leitman D, Cohen I, Shtivelman E, Fong S.

Int J Cancer. 2010 Sep 1;127(5):1209-19. doi: 10.1002/ijc.25116.

13.

Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress.

King FW, Fong S, Griffin C, Shoemaker M, Staub R, Zhang YL, Cohen I, Shtivelman E.

PLoS One. 2009 Sep 30;4(9):e7283. doi: 10.1371/journal.pone.0007283.

14.

Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells.

Fong S, Shoemaker M, Cadaoas J, Lo A, Liao W, Tagliaferri M, Cohen I, Shtivelman E.

Cancer Biol Ther. 2008 Apr;7(4):577-86. Epub 2008 Jan 7.

PMID:
18305410
15.

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D.

Breast Cancer Res Treat. 2007 Sep;105(1):17-28. Epub 2006 Nov 17.

PMID:
17111207
16.

Inhibition of nuclear import by the proapoptotic protein CC3.

King FW, Shtivelman E.

Mol Cell Biol. 2004 Aug;24(16):7091-101.

17.

AHNAK interacts with the DNA ligase IV-XRCC4 complex and stimulates DNA ligase IV-mediated double-stranded ligation.

Stiff T, Shtivelman E, Jeggo P, Kysela B.

DNA Repair (Amst). 2004 Mar 4;3(3):245-56.

PMID:
15177040
18.

Inhibition of Chk1 by activated PKB/Akt.

King FW, Skeen J, Hay N, Shtivelman E.

Cell Cycle. 2004 May;3(5):634-7. Epub 2004 May 31.

PMID:
15107605
20.
21.
22.

A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle.

Shtivelman E, Sussman J, Stokoe D.

Curr Biol. 2002 Jun 4;12(11):919-24.

23.

Protein kinase B phosphorylates AHNAK and regulates its subcellular localization.

Sussman J, Stokoe D, Ossina N, Shtivelman E.

J Cell Biol. 2001 Sep 3;154(5):1019-30.

24.

Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro.

NicAmhlaoibh R, Shtivelman E.

Oncogene. 2001 Jan 11;20(2):270-5.

25.

Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis.

Whitman S, Wang X, Shalaby R, Shtivelman E.

Mol Cell Biol. 2000 Jan;20(2):583-93.

26.

SCID-hu mice for the study of human cancer metastasis.

Namikawa R, Shtivelman E.

Cancer Chemother Pharmacol. 1999;43 Suppl:S37-41.

PMID:
10357557
27.

Systemic gene delivery expands the repertoire of effective antiangiogenic agents.

Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ.

J Biol Chem. 1999 May 7;274(19):13338-44.

28.
29.

Colonization of human lung grafts in SCID-hu mice by human colon carcinoma cells.

Sampson-Johannes A, Wang W, Shtivelman E.

Int J Cancer. 1996 Mar 15;65(6):864-9.

30.
31.

Localization of the human AHNAK/desmoyokin gene (AHNAK) to chromosome band 11q12 by somatic cell hybrid analysis and fluorescence in situ hybridization.

Kudoh J, Wang Y, Minoshima S, Hashimoto T, Amagai M, Nishikawa T, Shtivelman E, Bishop JM, Shimizu N.

Cytogenet Cell Genet. 1995;70(3-4):218-20.

PMID:
7789175
32.
33.

A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure.

Shtivelman E, Cohen FE, Bishop JM.

Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5472-6. Erratum in: Proc Natl Acad Sci U S A 1993 May 1;90(9):4328.

34.

Expression of CD44 is repressed in neuroblastoma cells.

Shtivelman E, Bishop JM.

Mol Cell Biol. 1991 Nov;11(11):5446-53.

35.

Effects of translocations on transcription from PVT.

Shtivelman E, Bishop JM.

Mol Cell Biol. 1990 Apr;10(4):1835-9.

36.

Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.

Shtivelman E, Henglein B, Groitl P, Lipp M, Bishop JM.

Proc Natl Acad Sci U S A. 1989 May;86(9):3257-60.

37.

The PVT gene frequently amplifies with MYC in tumor cells.

Shtivelman E, Bishop JM.

Mol Cell Biol. 1989 Mar;9(3):1148-54.

38.

bcr genes and transcripts.

Lifshitz B, Fainstein E, Marcelle C, Shtivelman E, Amson R, Gale RP, Canaani E.

Oncogene. 1988 Feb;2(2):113-7.

PMID:
3285291
39.

Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints.

Croce CM, Huebner K, Isobe M, Fainstain E, Lifshitz B, Shtivelman E, Canaani E.

Proc Natl Acad Sci U S A. 1987 Oct;84(20):7174-8.

40.

bcr-abl RNA in patients with chronic myelogenous leukemia.

Shtivelman E, Gale RP, Dreazen O, Berrebi A, Zaizov R, Kubonishi I, Miyoshi I, Canaani E.

Blood. 1987 Mar;69(3):971-3.

41.

Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E.

Cell. 1986 Oct 24;47(2):277-84.

PMID:
3021337
42.

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Shtivelman E, Lifshitz B, Gale RP, Canaani E.

Nature. 1985 Jun 13-19;315(6020):550-4.

PMID:
2989692
43.

Frequent generation of nonrescuable reorganized Moloney murine sarcoma viral genomes.

Shtivelman E, Zakut R, Canaani E.

Proc Natl Acad Sci U S A. 1984 Jan;81(2):294-8.

Supplemental Content

Loading ...
Support Center